Merck’s Welireg Could Expand Into Broader Kidney Cancer Indication With Phase III Data

 
• By Alaric DeArment

The drug maker announced Phase III results for the HIF-2α inhibitor in renal cell carcinoma patients with disease progression following PD-1/PD-L1 and anti-VEGF therapy.

Merck announced results for Welireg in renal cell carcinoma after checkpoint inhibitor and anti-VEGF treatment • Source: Shutterstock

More from Clinical Trials

More from R&D